Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
α-Interferon combination therapy of resistant myeloma
R. Alexanian
, B. Barlogie
, J. Gutterman
Research output
:
Contribution to journal
›
Article
›
peer-review
28
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'α-Interferon combination therapy of resistant myeloma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Interferon-α (IFN-α)
100%
Myeloma
100%
Combination Therapy
100%
Multiple Myeloma
25%
Prognostic Features
25%
Response Rate
25%
Advanced Disease
25%
Survival Time
25%
High-dose Dexamethasone
25%
Bone Marrow Cells
25%
Intensive Care Medicine
25%
Stem Cell Support
25%
Disease Resistant
25%
VAD Regimen
25%
Blood Stem Cells
25%
Medicine and Dentistry
Interferon
100%
Combination Therapy
100%
Myeloma
100%
Drug Megadose
25%
Dexamethasone
25%
Intensive Care
25%
Multiple Myeloma
25%
Identified Patient
25%
Survival Time
25%
Stem Cell
25%
Diseases
25%
Nursing and Health Professions
Combination Therapy
100%
Interferon
100%
Myeloma
100%
Drug Megadose
25%
Dexamethasone
25%
Intensive Care
25%
Multiple Myeloma
25%
Survival Time
25%
Diseases
25%
Pharmacology, Toxicology and Pharmaceutical Science
Interferon
100%
Combination Therapy
100%
Myeloma
100%
Dexamethasone
25%
Survival Time
25%
Multiple Myeloma
25%
Diseases
25%